Building an Understanding of the Value of Docetaxel Plus Hormone Therapy in Prostate Cancer: An Ever-growing Evidence Base

Eur Urol Oncol. 2018 Dec;1(6):459-460. doi: 10.1016/j.euo.2018.10.004. Epub 2018 Nov 10.

Authors

Richard De Abreu Lourenco¹, Scott G Williams²

Affiliations

¹ Centre for Health Economics Research and Evaluation, University of Technology, Sydney, Australia. Electronic address: richard.deabreulourenco@chere.uts.edu.au.
² Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia.

PMID: 31158088
DOI: 10.1016/j.euo.2018.10.004

No abstract available

Publication types

Editorial
Comment

MeSH terms

Androgen Antagonists
Cost-Benefit Analysis
Docetaxel*
Humans
Male
Prostatic Neoplasms*

Substances

Androgen Antagonists
Docetaxel